Scientists Find New Alzheimer's Drug That Slows Brain Damage

After nearly 20 years of research, scientists have identified a promising new weapon against Alzheimer's disease that works differently than any existing treatment.

Researchers at ETH Zurich developed an experimental compound called Compound 10 that targets a protein called GRK2. In studies with mice, the treatment reduced nerve cell loss, helped animals live longer, and even appeared to slow signs of aging like gray hair.

The discovery began when Professor Ursula Quitterer received brain tissue samples from patients in Cairo. Her team noticed that people with dementia had unusually high levels of an inactive form of GRK2 in their brains.

This inactive version of the protein behaves like a troublemaker. It clumps together inside nerve cells and blocks the mitochondria, which are the power plants that give cells energy. When mitochondria can't function properly, brain cells struggle and eventually die.

The researchers also found that these GRK2 clusters increase production of amyloid beta, the sticky protein fragment famous for its role in Alzheimer's. This creates a vicious cycle where amyloid beta causes more stress, which leads to more GRK2 buildup, which accelerates the disease.

Compound 10 breaks this cycle by preventing GRK2 from forming harmful clusters. When mitochondria work properly again, nerve cells stay healthier and amyloid deposits decrease.

The Ripple Effect

The benefits extended beyond brain health. Treated mice showed improved heart function and fewer age-related changes throughout their bodies. The compound appears to influence multiple aspects of healthy aging, not just dementia.

The research took two decades partly because Alzheimer's studies require older mice, typically between one and a half and two years old. Each experiment required months or years before the team could draw conclusions and move to the next stage.

ETH Zurich has filed a patent application and is now seeking a pharmaceutical company to advance Compound 10 toward human trials. Current Alzheimer's medications only delay progression by a few months at best, so discovering an entirely new target protein opens exciting possibilities.

Quitterer believes combining Compound 10 with existing treatments could eventually offer greater benefits. While much more research is needed before human testing can begin, patients and families now have a new reason for hope in the fight against a disease that affects millions worldwide.